KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2016 - 2025)

Alnylam Pharmaceuticals' Other Non Operating Income history spans 16 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 95.84% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached -$74.7 million, up 58.63%, while the annual FY2025 figure was $5.2 million, 102.88% up from the prior year.
  • Other Non Operating Income reached -$3.4 million in Q4 2025 per ALNY's latest filing, up from -$74.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $55.0 million in Q4 2022 to a low of -$80.8 million in Q4 2024.
  • Average Other Non Operating Income over 5 years is -$24.8 million, with a median of -$24.4 million recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: surged 3082.32% in 2021, then plummeted 532.4% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$28.5 million in 2021, then surged by 293.36% to $55.0 million in 2022, then crashed by 136.99% to -$20.4 million in 2023, then crashed by 297.26% to -$80.8 million in 2024, then skyrocketed by 95.84% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Other Non Operating Income are -$3.4 million (Q4 2025), -$74.1 million (Q3 2025), and -$6.4 million (Q2 2025).